Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

@article{Reddy2008ImmunomodulatoryDS,
  title={Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.},
  author={N. Madhu Sudhana Reddy and Francisco J Hernandez-Ilizaliturri and George Michael Deeb and Mark F. Roth and Mary Vaughn and Joy Knight and Paul Wallace and Myron S. Czuczman},
  journal={British journal of haematology},
  year={2008},
  volume={140 1},
  pages={36-45}
}
The immunomodulatory drugs (IMiDs) lenalidomide and actimid (also known as CC-4047) are thalidomide analogues which are more potent than their parental compound. In combination with rituximab, we have previously demonstrated that IMiDs have synergistic in vivo anti-tumour activity in preclinical studies in a human lymphoma severe combined immunodeficiency mouse model. This report further explored the mechanisms by which IMiDs exert their anti-lymphoma effects. Following exposure of subcutaneous… CONTINUE READING